# Incidence, Prevalence, and Symptom Burden Associated With Advanced Renal Cell Carcinoma in Commercially Insured Population (Pharmetrics)

> **NCT01381601** · — · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 1 (actual)

## Conditions studied

- Carcinoma, Renal Cell

## Interventions

- **DRUG:** Targeted agents indicated in management of advanced/metastatic RCC (sunitinib, sorafenib, bevacizumab, and pazopanib)

## Key facts

- **NCT ID:** NCT01381601
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2011-03
- **Primary completion:** 2011-10
- **Final completion:** 2011-10
- **Target enrollment:** 1 (ACTUAL)
- **Last updated:** 2013-05-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01381601

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01381601, "Incidence, Prevalence, and Symptom Burden Associated With Advanced Renal Cell Carcinoma in Commercially Insured Population (Pharmetrics)". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01381601. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*